Navigation Links
Quincy Bioscience Announces Encouraging Preliminary Results of Randomized, Double-Blind, Placebo-Controlled Memory Study
Date:6/24/2010

Quincy Bioscience, a research-based biotechnology company, announced interim results from the Prevagen Memory Study. The Prevagen Memory Study is a three-month long, randomized, double-blind, placebo controlled study using both qualitative Quality of Life surveys and a quantitative, computer-based set of cognitive tests developed by Cogstate Ltd.

Madison, WI (Vocus) June 24, 2010 -- Quincy Bioscience, a research-based biotechnology company, announced interim results from the Prevagen Memory Study. The Prevagen Memory Study is a three-month long, randomized, double-blind, placebo controlled study using both qualitative Quality of Life surveys and a quantitative, computer-based set of cognitive tests developed by Cogstate Ltd.

Prevagen showed statistically significant improvement over placebo at Day 60 in measures of spatial working memory and executive function in thirty five generally healthy adults reporting memory concerns prior to the start of the trial. The Prevagen arm showed a 14% reduction in the number of total errors compared to Day 0. The average age of this initial cohort was 61 years old and sixty eight percent of the participants were female. A statistically significant improvement was also seen in the change from baseline (Day 0) measurements. “We are encouraged by what this preliminary look at the data from this study has shown us,” said KC Lerner, Manager of Business Development.

Prevagen contains the calcium-binding protein apoaequorin. Apoaequorin has demonstrated neuroprotection in pre-clinical studies performed at the University of Wisconsin-Milwaukee. Apoaequorin was originally isolated from Aequorea victoria, a species of jellyfish found in the Puget Sound.

“The relationship between intracellular calcium imbalance and age-related cognitive decline is well-established. The data shows that Prevagen is a new tool for staying cognitively fit as we age. With 78 million baby boomers getting older every day, helping people with memory concerns is our first priority,” said Quincy Bioscience President Mark Underwood. Quincy Bioscience is also looking at several health conditions that are believed to be the result of disruptions in calcium homeostasis and intends to study the effect of Prevagen in these conditions.

About Quincy Bioscience
Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms.

###

Read the full story at http://www.prweb.com/releases/quincybioscience/memorydata/prweb4188374.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Quincy Bioscience Launches HOPETrials.com; Research Studies More Accessible For Participants
2. Quincy Bioscience Sponsors Multiple Sclerosis (MS) Scholarship Program
3. Euthymics Bioscience Collaborates with GlobalSign and SafeNet to Provide an FDA Approved Electronic Signature Solution
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results
5. Thriving Bioscience Region Leaves Its Mark
6. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
7. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
8. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
9. Digital Pathology Services Firm Flagship Biosciences Appoints New CEO
10. Exalenz Bioscience Expands Market Coverage for the BreathID Breath Test System
11. Martek Biosciences and the National Center for Creative Aging Introduce New Brain Health Awareness Campaign, "Beautiful Minds: Finding Your Lifelong Potential"
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Quincy Bioscience Announces Encouraging Preliminary Results of Randomized, Double-Blind, Placebo-Controlled Memory Study
(Date:5/6/2016)... ... May 06, 2016 , ... The ... digital-based Zika education initiative in Puerto Rico. Radio messages set to debut on ... from physicians and pharmacists about ways to protect themselves and their unborn children ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... master charity program created to support and assist the people of their local ... closely with nonprofit organizations and community leaders. Their desire is to bring awareness ...
(Date:5/6/2016)... ... ... US Sports Camps has collaborated with State Rugby Organization (SRO), Rugby Oregon, ... Employing world-class rugby figures, including former Team USA players and college coaches, this program ... match play, fitness and more. , “US Sports Camps is honored to be working ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... reduce fat areas around the body, is the most popular among body sculpting ... released make perfect sense to cosmetic surgeon Dr. Richard Buckley, medical director of ...
(Date:5/6/2016)... ... ... From the Speaker Podium to the Exhibit Floor at Booth#514, Worldwide Leading Contact ... Engagement at SpeechTek 2016 Event, taking place May 23-25 at the Omni Shoreham in ... on “5 Customer Engagement Strategies to improve Customer Satisfaction in your Contact Center” on ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... ALBANY, New York , May 4, 2016 /PRNewswire/ ... published by Transparency Market Research entitled "Brain Computer Interface Market ... Forecast 2016 - 2024," the  global brain computer interface (BCI) ... bn by 2024. The market is estimated to expand ... period from 2016 to 2024. A BCI ...
(Date:5/4/2016)... Yissum Research Development Company of the ... had signed an exclusive world-wide licensing and research agreement ... degradation and immunomodulatory drugs for cancer and immune dysfunction, ... first-in-class therapy for hematologic and solid malignancies. Financial terms ... novel technology was developed by Yinon Ben-Neriah , ...
(Date:5/4/2016)... 2016 Research and ... Acute Ischemic Stroke Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Stroke Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Ischemic Stroke epidemiology, Acute ...
Breaking Medicine Technology: